ArticleClinical cancer research : an official journal of the American Association for Cancer Research2012
An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 36 citations in OpenAlex.
- Brain tumors induce immunoregulatory dendritic cells in draining lymph nodes that can be targeted by OX40 agonist treatment.Journal for immunotherapy of cancer · 2025Article
- Article
- An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma.Frontiers in oncology · 2022Article
- Whole-body PET Imaging of T-cell Response to Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Sendai virus-based immunoadjuvant in hydrogel vaccine intensity-modulated dendritic cells activation for suppressing tumorigenesis.Bioactive materials · 2021Article
- Protective low-avidity anti-tumour CD8+ T cells are selectively attenuated by regulatory T cells.Immunotherapy advances · 2021Article
- Recombinant Costimulatory Fusion Proteins as Functional Immunomodulators Enhance Antitumor Activity in Murine B16F10 Melanoma.Vaccines · 2020Article
- A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.Journal of autoimmunity · 2018Review
- Eradication of spontaneous malignancy by local immunotherapy.Science translational medicine · 2018Article
- Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.Neuro-oncology · 2018Article
- Synergy of vaccination and agonist OX40 treatment-toward a mechanism-driven combination of glioma immunotherapy.Neuro-oncology · 2018Article
- Article
- TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.Current opinion in immunology · 2017Review
- The Microenvironmental Landscape of Brain Tumors.Cancer cell · 2017Review
- CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas.Cancers · 2016Review
- Heterologous Vaccination and Checkpoint Blockade Synergize To Induce Antileukemia Immunity.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.Journal for immunotherapy of cancer · 2016Article
- Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.Journal of visualized experiments : JoVE · 2015Article
- Review
- OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.Frontiers in oncology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
purposeWe tested the combination of a tumor lysate vaccine with a panel of costimulatory molecules to identify an immunotherapeutic approach capable of curing established murine gliomas. EXPERIMENTAL
designGlioma-bearing mice were primed with a tumor lysate vaccine, followed by systemic administration of the following costimulatory ligands: OX40L, CD80, 4-1BBL, and GITRL, which were fused to the Fc portion of human immunoglobulin. Lymphocytes and mRNA were purified from the brain tumor site for immune monitoring studies. Numerous variations of the vaccine and Fc-OX40L regimen were tested alone or in combination with temozolomide.
resultsLysate vaccinations combined with Fc-OX40L led to the best overall survival, yielding cure rates of 50% to 100% depending on the timing, regimen, and combination with temozolomide. Cured mice that were rechallenged with glioma cells rejected the challenge, showing immunologic memory. Lymphocytes isolated from the draining lymph nodes of vaccine/Fc-OX40L-treated mice had superior tumoricidal function relative to all other groups. Vaccine/Fc-OX40L-treated mice exhibited a significant increase in proliferation of brain-infiltrating CD4 and CD8 T cells, as indicated by Ki67 staining. Fc-OX40L had single-agent activity in transplanted and spontaneous glioma models, and the pattern of inflammatory gene expression in the tumor predicted the degree of therapeutic response.
conclusionsThese data show that Fc-OX40L has unique and potent activity against experimental gliomas and warrants further testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.